Developer docs
API playgroundTry for free, no card

Search company profiles

Verve Therapeutics

Full company profile

uuid000042o

Namestring
Verve Therapeutics
Legal namestring
Verve Therapeutics, Inc.
Websiteurl
vervetx.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Verve Therapeutics is a clinical-stage biotechnology company developing single-course in vivo gene editing medicines that target cardiovascular disease, the leading global cause of mortality. Founded in 2018 and headquartered in Boston, Massachusetts, the company pursues a one-time, liver-directed intervention designed to permanently lower disease-driving lipid biomarkers such as LDL-C and Lp(a) in patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), atherosclerotic cardiovascular disease (ASCVD), and other dyslipidemias. Verve became a wholly-owned subsidiary of Eli Lilly and Company on July 25, 2025, following an acquisition valued at up to $1.3 billion in upfront cash and contingent value rights.

Verve's technology platform centers on in vivo base editing using an adenine base editor (ABE) that makes a single A-to-G nucleotide change in DNA without introducing a double-stranded break. The gene editor is delivered to hepatocytes via the company's proprietary GalNAc-LNP system, in which a GalNAc ligand binds both the asialoglycoprotein receptor and the LDL receptor — a design that uniquely enables gene editor delivery even in patients lacking functional LDL receptors (e.g., HoFH). The pipeline comprises VERVE-102 (lead candidate; inactivates PCSK9; Heart-2 Phase 1b in HeFH and premature coronary artery disease, with FDA Fast Track designation); VERVE-201 (inactivates ANGPTL3; Pulse-1 Phase 1b in HoFH and refractory hypercholesterolemia); VERVE-301 (preclinical; targets LPA/Lp(a) in collaboration with Eli Lilly); and the earlier-generation VERVE-101, which provided first-in-human proof-of-concept for in vivo base editing in 2022.

Verve's business model has been that of a pre-revenue clinical-stage biotech. Operating capital was raised through venture financing (Series A $58.5M, Series A2 $63M, Series B $94M), an IPO on NASDAQ in June 2021, follow-on public offerings, and corporate partnership economics. The June 2023 Eli Lilly Lp(a) collaboration — expanded in October 2023 to include PCSK9 and ANGPTL3 programs — provided a $60M upfront payment and established milestone- and royalty-based economics. Following the July 2025 acquisition, commercialization of any approved single-course gene editing therapy is expected to leverage Eli Lilly's cardiometabolic sales infrastructure. No product pricing has been disclosed, as all candidates remain investigational; comparable precedent (Hemgenix) suggests potential per-patient pricing above $1M for an approved single-course cardiovascular gene editing therapy, but Verve has no approved products at this time.

Short descriptiontext

Verve Therapeutics is a clinical-stage biotechnology company developing single-course in vivo base editing medicines that inactivate PCSK9, ANGPTL3, and LPA genes in the liver to durably lower LDL-C and Lp(a) for cardiovascular disease patients. Acquired by Eli Lilly in July 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
in vivo gene editing, cardiovascular gene editing, base editing therapeutics, lipid nanoparticle delivery, PCSK9 gene editing
Product category
Cardiovascular Genetic Medicines
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pre-revenue Clinical Development
TypeOne Time License
Description

Verve Therapeutics is a clinical-stage biotechnology company that, prior to acquisition, generated no product revenue. Its programs (VERVE-102, VERVE-201, VERVE-301) are investigational and not yet approved by any health authority. Revenue, if achieved, is expected to come from one-time treatment dosing of single-course gene editing medicines rather than chronic recurring prescriptions.

vervetx.com
2Collaboration and Licensing Revenue (Lilly)
TypeLicensing Royalties
Description

In June 2023, Verve established a global collaboration with Eli Lilly for its in vivo gene editing program targeting Lp(a), with $60 million in committed investment including upfront payment, milestones, and royalties. In October 2023, the relationship expanded to include Verve's in vivo PCSK9 and ANGPTL3 programs. Revenue streams included upfront payments, milestone payments, and future royalties on commercialized products.

fiercebiotech.com
3Acquisition Proceeds (Eli Lilly Takeover)
TypeTransaction Fee
Description

In June 2025, Eli Lilly agreed to acquire Verve for up to $1.3 billion ($10.50 per share upfront plus up to $300 million in contingent value rights/clinical milestones), with the acquisition completed in July 2025. Verve Therapeutics now operates as a wholly-owned subsidiary of Eli Lilly, with commercialization handled within Lilly's cardiometabolic franchise.

barrons.com
Cost components4 values
Technology or R&D, Personnel, Operations, Others
Pricing details1 tier
1Pricing not publicly disclosed; investigational single-course gene editing medicines
ModelOther
Notes

Quote-based / Not publicly disclosed. Products are clinical-stage and not commercially available.

vervetx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1VERVE-102
Description

In vivo base editing medicine targeting the PCSK9 gene in the liver to durably lower LDL-C.

vervetx.com
+3 more records
Core offering1 text field

Verve Therapeutics is a clinical-stage biotechnology company developing single-course, in vivo base editing medicines designed to permanently turn off specific genes (PCSK9, ANGPTL3, LPA) in the liver to durably lower LDL cholesterol, triglycerides, and lipoprotein(a) for patients with atherosclerotic cardiovascular disease. The lead programs (VERVE-102, VERVE-201, VERVE-301) are delivered via Verve's proprietary GalNAc-LNP delivery system and are administered as a one-time intravenous infusion, replacing decades of chronic statin or PCSK9 inhibitor therapy.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Verve Therapeutics is a clinical-stage biotechnology company (now a wholly-owned subsidiary of Eli Lilly and Company since July 2025) that operates as a single-platform company organized around an in vivo base editing technology platform with multiple pipeline product candidates. The core base editing platform powers each named program: VERVE-102 (lead PCSK9-targeting clinical candidate delivered via the proprietary GalNAc-LNP, in the Heart-2 Phase 1b trial); VERVE-201 (ANGPTL3-targeting clinical candidate delivered via GalNAc-LNP, in the Pulse-1 Phase 1b trial); VERVE-301 (preclinical LPA/Lp(a)-targeting program in collaboration with Eli Lilly); and the earlier-generation VERVE-101 (PCSK9, first-in-human base editing clinical candidate). All clinical-stage candidates share Verve's proprietary GalNAc-LNP liver delivery technology as the common delivery module. The company's near-term roadmap is to initiate a Phase 2 trial of VERVE-102 while advancing VERVE-201 and the Lp(a) program.

Product and service4 records
1VERVE-102
CategoryLead clinical-stage in vivo base editing medicine (PCSK9)
Description

Investigational in vivo base editing medicine that permanently inactivates the PCSK9 gene in the liver to durably lower blood LDL-C. Administered as a single intravenous infusion over a few hours via Verve's proprietary GalNAc-LNP. Being evaluated in the Heart-2 Phase 1b trial in patients with heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease (CAD).

2VERVE-201
CategoryClinical-stage in vivo base editing medicine (ANGPTL3)
Description

Investigational single-course base editing medicine that permanently inactivates the ANGPTL3 gene in the liver to reduce LDL-C and triglyceride levels. Uses Verve's proprietary GalNAc-LNP delivery system. Being developed for homozygous familial hypercholesterolemia (HoFH) and refractory hypercholesterolemia, evaluated in the Pulse-1 Phase 1b trial.

3VERVE-301
CategoryPreclinical in vivo gene editing medicine (LPA/Lp(a))
Description

Investigational single-course gene editing treatment that permanently inactivates the LPA gene in the liver to reduce lipoprotein(a) (Lp(a)) levels. Leverages Verve's GalNAc-LNP delivery system. Preclinical-stage program targeting atherosclerotic cardiovascular disease with high Lp(a), advanced in collaboration with Eli Lilly.

4VERVE-101
CategoryEarlier-generation clinical-stage in vivo base editing medicine (PCSK9)
Description

Earlier-generation clinical-stage in vivo base editing medicine targeting the PCSK9 gene in the liver, dosed in the heart-1 Phase 1b clinical trial as a potential treatment for heterozygous familial hypercholesterolemia (HeFH). Provided first human proof-of-concept for in vivo base editing with dose-dependent reductions in LDL-C and blood PCSK9 protein.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Beam Therapeutics is a Cambridge-based clinical-stage biotechnology company developing base editing medicines, the same core technology platform as Verve. It targets multiple disease areas and is the closest direct technical peer to Verve's in vivo base editing approach.

TypeDirect peer
Description

Intellia is a clinical-stage company developing in vivo CRISPR/Cas9 gene editing therapies (e.g., NTLA-2001/2002 for transthyretin amyloidosis). It is the leading direct competitor to Verve in systemic in vivo gene editing for chronic disease.

TypeBroad incumbent
Description

CRISPR Therapeutics is a commercial-stage gene editing company (Casgevy, in partnership with Vertex) using CRISPR/Cas9. It is a broader incumbent in gene editing with established regulatory and commercial capabilities that Verve now accesses via Eli Lilly.

TypeDirect peer
Description

Editas Medicine is a clinical-stage gene editing company using CRISPR/Cas9 and Cas12a for multiple indications. It is a direct peer in the genome editing modality space, though with more ex vivo and ophthalmology focus than Verve's liver-directed in vivo approach.

TypeEmerging player
Description

Prime Medicine is developing prime editing, a next-generation gene editing modality that like Verve's base editing avoids double-stranded DNA breaks. It is an emerging peer with partial technical overlap and similar chronic disease ambitions.

TypeEmerging player
Description

Korro Bio is developing RNA editing (ADAR-based) medicines with a stated focus on cardiometabolic indications. It is an emerging player targeting overlapping cardiovascular patient populations via an adjacent editing modality.

TypeEmerging player
Description

Tenaya Therapeutics develops genetic medicines specifically for heart disease, including gene therapy and gene editing approaches for cardiomyopathies and heart failure. It is an emerging peer targeting the same cardiovascular genetics opportunity from a different modality angle.

TypeEmerging player
Description

Lexeo Therapeutics is a clinical-stage gene therapy company focused on cardiovascular diseases including familial cardiomyopathy and dyslipidemias. It is an emerging peer addressing overlapping cardiovascular indications with AAV-based gene therapy rather than base editing.

TypeBroad incumbent
Description

Sangamo Therapeutics is a clinical-stage genomic medicine company developing zinc finger nucleases and other genome editing/regulation approaches. It is a broader incumbent in the genome editing space, historically focused on in vivo applications.

TypeBroad incumbent
Description

Vertex established a 2022 collaboration with Verve for in vivo liver gene editing, holds approved Casgevy, and has stated interest in genetic medicines for serious diseases. It is a broad incumbent and strategic counterparty relevant to the gene editing competitive landscape.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Verve Therapeutics

Cardiovascular Genetic Medicinesvervetx.com

Verve Therapeutics is a clinical-stage biotechnology company developing single-course in vivo base editing medicines that inactivate PCSK9, ANGPTL3, and LPA genes in the liver to durably lower LDL-C and Lp(a) for cardiovascular disease patients. Acquired by Eli Lilly in July 2025.

What Verve Therapeutics does

Verve Therapeutics is a clinical-stage biotechnology company developing single-course in vivo gene editing medicines that target cardiovascular disease, the leading global cause of mortality. Founded in 2018 and headquartered in Boston, Massachusetts, the company pursues a one-time, liver-directed intervention designed to permanently lower disease-driving lipid biomarkers such as LDL-C and Lp(a) in patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), atherosclerotic cardiovascular disease (ASCVD), and other dyslipidemias. Verve became a wholly-owned subsidiary of Eli Lilly and Company on July 25, 2025, following an acquisition valued at up to $1.3 billion in upfront cash and contingent value rights.

Verve's technology platform centers on in vivo base editing using an adenine base editor (ABE) that makes a single A-to-G nucleotide change in DNA without introducing a double-stranded break. The gene editor is delivered to hepatocytes via the company's proprietary GalNAc-LNP system, in which a GalNAc ligand binds both the asialoglycoprotein receptor and the LDL receptor — a design that uniquely enables gene editor delivery even in patients lacking functional LDL receptors (e.g., HoFH). The pipeline comprises VERVE-102 (lead candidate; inactivates PCSK9; Heart-2 Phase 1b in HeFH and premature coronary artery disease, with FDA Fast Track designation); VERVE-201 (inactivates ANGPTL3; Pulse-1 Phase 1b in HoFH and refractory hypercholesterolemia); VERVE-301 (preclinical; targets LPA/Lp(a) in collaboration with Eli Lilly); and the earlier-generation VERVE-101, which provided first-in-human proof-of-concept for in vivo base editing in 2022.

Verve's business model has been that of a pre-revenue clinical-stage biotech. Operating capital was raised through venture financing (Series A $58.5M, Series A2 $63M, Series B $94M), an IPO on NASDAQ in June 2021, follow-on public offerings, and corporate partnership economics. The June 2023 Eli Lilly Lp(a) collaboration — expanded in October 2023 to include PCSK9 and ANGPTL3 programs — provided a $60M upfront payment and established milestone- and royalty-based economics. Following the July 2025 acquisition, commercialization of any approved single-course gene editing therapy is expected to leverage Eli Lilly's cardiometabolic sales infrastructure. No product pricing has been disclosed, as all candidates remain investigational; comparable precedent (Hemgenix) suggests potential per-patient pricing above $1M for an approved single-course cardiovascular gene editing therapy, but Verve has no approved products at this time.

Verve Therapeutics firmographics

Firmographics
Name
Verve Therapeutics
Legal name
Verve Therapeutics, Inc.
Website
https://vervetx.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
101–250 employees
Short description
Verve Therapeutics is a clinical-stage biotechnology company developing single-course in vivo base editing medicines that inactivate PCSK9, ANGPTL3, and LPA genes in the liver to durably lower LDL-C and Lp(a) for cardiovascular disease patients. Acquired by Eli Lilly in July 2025.
Ownership category
akta.pro rank

Where Verve Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Verve Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Pre-revenue Clinical Development: Verve Therapeutics is a clinical-stage biotechnology company that, prior to acquisition, generated no product revenue. Its programs (VERVE-102, VERVE-201, VERVE-301) are investigational and not yet approved by any health authority. Revenue, if achieved, is expected to come from one-time treatment dosing of single-course gene editing medicines rather than chronic recurring prescriptions.
  2. Collaboration and Licensing Revenue (Lilly): In June 2023, Verve established a global collaboration with Eli Lilly for its in vivo gene editing program targeting Lp(a), with $60 million in committed investment including upfront payment, milestones, and royalties. In October 2023, the relationship expanded to include Verve's in vivo PCSK9 and ANGPTL3 programs. Revenue streams included upfront payments, milestone payments, and future royalties on commercialized products.
  3. Acquisition Proceeds (Eli Lilly Takeover): In June 2025, Eli Lilly agreed to acquire Verve for up to $1.3 billion ($10.50 per share upfront plus up to $300 million in contingent value rights/clinical milestones), with the acquisition completed in July 2025. Verve Therapeutics now operates as a wholly-owned subsidiary of Eli Lilly, with commercialization handled within Lilly's cardiometabolic franchise.

Pricing tiers

ModelBillingPrice
Other—Pricing not publicly disclosed; investigational single-course gene editing medicines

Go-to-market motion2 records

Verve Therapeutics product offering

Product offering

Core offering

Verve Therapeutics is a clinical-stage biotechnology company developing single-course, in vivo base editing medicines designed to permanently turn off specific genes (PCSK9, ANGPTL3, LPA) in the liver to durably lower LDL cholesterol, triglycerides, and lipoprotein(a) for patients with atherosclerotic cardiovascular disease. The lead programs (VERVE-102, VERVE-201, VERVE-301) are delivered via Verve's proprietary GalNAc-LNP delivery system and are administered as a one-time intravenous infusion, replacing decades of chronic statin or PCSK9 inhibitor therapy.

Product overview

Verve Therapeutics is a clinical-stage biotechnology company (now a wholly-owned subsidiary of Eli Lilly and Company since July 2025) that operates as a single-platform company organized around an in vivo base editing technology platform with multiple pipeline product candidates. The core base editing platform powers each named program: VERVE-102 (lead PCSK9-targeting clinical candidate delivered via the proprietary GalNAc-LNP, in the Heart-2 Phase 1b trial); VERVE-201 (ANGPTL3-targeting clinical candidate delivered via GalNAc-LNP, in the Pulse-1 Phase 1b trial); VERVE-301 (preclinical LPA/Lp(a)-targeting program in collaboration with Eli Lilly); and the earlier-generation VERVE-101 (PCSK9, first-in-human base editing clinical candidate). All clinical-stage candidates share Verve's proprietary GalNAc-LNP liver delivery technology as the common delivery module. The company's near-term roadmap is to initiate a Phase 2 trial of VERVE-102 while advancing VERVE-201 and the Lp(a) program.

Differentiator

Problem solved

Functional benefit

Brands

  • VERVE-102: In vivo base editing medicine targeting the PCSK9 gene in the liver to durably lower LDL-C.
  • VERVE-201
  • VERVE-301
  • GalNAc-LNP

Products and services

  • VERVE-102 Investigational in vivo base editing medicine that permanently inactivates the PCSK9 gene in the liver to durably lower blood LDL-C. Administered as a single intravenous infusion over a few hours via Verve's proprietary GalNAc-LNP. Being evaluated in the Heart-2 Phase 1b trial in patients with heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease (CAD).
  • VERVE-201 Investigational single-course base editing medicine that permanently inactivates the ANGPTL3 gene in the liver to reduce LDL-C and triglyceride levels. Uses Verve's proprietary GalNAc-LNP delivery system. Being developed for homozygous familial hypercholesterolemia (HoFH) and refractory hypercholesterolemia, evaluated in the Pulse-1 Phase 1b trial.
  • VERVE-301 Investigational single-course gene editing treatment that permanently inactivates the LPA gene in the liver to reduce lipoprotein(a) (Lp(a)) levels. Leverages Verve's GalNAc-LNP delivery system. Preclinical-stage program targeting atherosclerotic cardiovascular disease with high Lp(a), advanced in collaboration with Eli Lilly.
  • VERVE-101 Earlier-generation clinical-stage in vivo base editing medicine targeting the PCSK9 gene in the liver, dosed in the heart-1 Phase 1b clinical trial as a potential treatment for heterozygous familial hypercholesterolemia (HeFH). Provided first human proof-of-concept for in vivo base editing with dose-dependent reductions in LDL-C and blood PCSK9 protein.

Companies that use Verve Therapeutics

Customer profile

Ideal customer profiles2 records

Verve Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Verve Therapeutics partnerships and signals

Strategic signal

Recent moves7 records

Expansion highlights6 records

Verve Therapeutics competitors and assessment

Company assessment

Direct peers

  • Beam Therapeutics: Beam Therapeutics is a Cambridge-based clinical-stage biotechnology company developing base editing medicines, the same core technology platform as Verve. It targets multiple disease areas and is the closest direct technical peer to Verve's in vivo base editing approach.
  • Intellia Therapeutics: Intellia is a clinical-stage company developing in vivo CRISPR/Cas9 gene editing therapies (e.g., NTLA-2001/2002 for transthyretin amyloidosis). It is the leading direct competitor to Verve in systemic in vivo gene editing for chronic disease.
  • Editas Medicine: Editas Medicine is a clinical-stage gene editing company using CRISPR/Cas9 and Cas12a for multiple indications. It is a direct peer in the genome editing modality space, though with more ex vivo and ophthalmology focus than Verve's liver-directed in vivo approach.

Broad incumbents

  • CRISPR Therapeutics: CRISPR Therapeutics is a commercial-stage gene editing company (Casgevy, in partnership with Vertex) using CRISPR/Cas9. It is a broader incumbent in gene editing with established regulatory and commercial capabilities that Verve now accesses via Eli Lilly.
  • Sangamo Therapeutics: Sangamo Therapeutics is a clinical-stage genomic medicine company developing zinc finger nucleases and other genome editing/regulation approaches. It is a broader incumbent in the genome editing space, historically focused on in vivo applications.
  • Vertex Pharmaceuticals: Vertex established a 2022 collaboration with Verve for in vivo liver gene editing, holds approved Casgevy, and has stated interest in genetic medicines for serious diseases. It is a broad incumbent and strategic counterparty relevant to the gene editing competitive landscape.

Emerging players

  • Prime Medicine: Prime Medicine is developing prime editing, a next-generation gene editing modality that like Verve's base editing avoids double-stranded DNA breaks. It is an emerging peer with partial technical overlap and similar chronic disease ambitions.
  • Korro Bio: Korro Bio is developing RNA editing (ADAR-based) medicines with a stated focus on cardiometabolic indications. It is an emerging player targeting overlapping cardiovascular patient populations via an adjacent editing modality.
  • Tenaya Therapeutics: Tenaya Therapeutics develops genetic medicines specifically for heart disease, including gene therapy and gene editing approaches for cardiomyopathies and heart failure. It is an emerging peer targeting the same cardiovascular genetics opportunity from a different modality angle.
  • Lexeo Therapeutics: Lexeo Therapeutics is a clinical-stage gene therapy company focused on cardiovascular diseases including familial cardiomyopathy and dyslipidemias. It is an emerging peer addressing overlapping cardiovascular indications with AAV-based gene therapy rather than base editing.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Verve Therapeutics social profiles

Digital presence

Verve Therapeutics compliance and trust

Trust signal

Compliance12 records

Verve Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Verve Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Verve Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Verve Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verve Therapeutics

What does Verve Therapeutics do?

Verve Therapeutics is a clinical-stage biotechnology company developing single-course, in vivo base editing medicines designed to permanently turn off specific genes (PCSK9, ANGPTL3, LPA) in the liver to durably lower LDL cholesterol, triglycerides, and lipoprotein(a) for patients with atherosclerotic cardiovascular disease. The lead programs (VERVE-102, VERVE-201, VERVE-301) are delivered via Verve's proprietary GalNAc-LNP delivery system and are administered as a one-time intravenous infusion, replacing decades of chronic statin or PCSK9 inhibitor therapy.

Is Verve Therapeutics a public or private company?

Verve Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Verve Therapeutics founded?

Verve Therapeutics was founded in 2018. It employs 101 to 250 people.

Where is Verve Therapeutics based?

Verve Therapeutics is headquartered in Boston, United States, in the North America region.

How does Verve Therapeutics make money?

Three revenue lines are on record. Pre-revenue Clinical Development is the primary driver. The others are collaboration and Licensing Revenue (Lilly) and acquisition Proceeds (Eli Lilly Takeover).

Who are Verve Therapeutics's main competitors?

Direct peers on record are Beam Therapeutics, Intellia Therapeutics and Editas Medicine. Broad incumbents are CRISPR Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals. Emerging players are Prime Medicine, Korro Bio, Tenaya Therapeutics and Lexeo Therapeutics.

Does Verve Therapeutics have an API?

No public API is recorded for Verve Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate크리스퍼 유전자 편집 치료 한 번으로 혈중 중성지방 3년간 감소 : 네이트 뉴스Researchers at Verve Therapeutics and a partner used CRISPR to edit liver cells in monkeys, keeping triglycerides and LDL cholesterol low for three years. The treatment reduced ANGPTL3 protein by 94%, triglycerides by 43%, and LDL by 13%. The team is now testing VERVE-201 in clinical trials for severe hypercholesterolemia.Business & FinancialHypercholesterolemia Drugs In Development 2026: Pipeline Therapies, Ongoing Trials, And Companies Driving Innovation EPIC BIO, Amytrx Therapeutics, Chroma Medicine, Verve Therapeutics, IncMerck's oral PCSK9 inhibitor Lipfendra received FDA approval in July 2026, reducing LDL-C by 56-59% versus placebo. Other pipeline drugs include Arrowhead's ARO-DIMER-PA and CRISPR's CTX310, with trials ongoing. The report also covers EPIC-221, AMTX 100, and VERVE-102.BioSpaceScribe’s early-stage IPO standout defies biotech’s derisking trendScribe Therapeutics, a biotech firm co-created by CRISPR pioneers, has seen its stock rise 43% since its $150 million IPO debut as it enters Phase 1 trials for STX-1150, an epigenetic treatment targeting cholesterol. The company has secured investments and partnerships with major pharmaceutical firms Sanofi and Eli Lilly, which provided external validation for its gene-editing platform. Analysts at Leerink Partners highlight that early clinical data readouts next year will serve as a critical value inflection point for the stock.TimesNowA Single Shot to Lower Bad Cholesterol? The Verve-102 Gene-Editing Breakthrough ExplainedVerve Therapeutics is developing Verve-102, an experimental gene-editing treatment designed to lower LDL cholesterol through a single intravenous infusion targeting the PCSK9 gene. Early Phase 1b trial results showed significant reductions in both PCSK9 and LDL levels that persisted for up to 18 months, though the therapy remains investigational and unapproved.TimesNowGoodbye Daily Statins? VERVE-102 Aims To Cut LDL Cholesterol In One ShotEarly clinical trial results for VERVE-102, a gene-editing therapy for lowering LDL cholesterol developed by Verve Therapeutics and acquired by Eli Lilly, showed that a single infusion reduced LDL cholesterol by up to 62% in participants with familial hypercholesterolemia or premature coronary artery disease. The Phase 1b Heart-2 trial demonstrated durable cholesterol reductions lasting up to 18 months with no treatment-related serious adverse events, suggesting gene-editing could transform cardiovascular treatment from chronic daily medication to a one-time intervention. The FDA has granted Fast Track designation to VERVE-102 given its potential to address a major unmet medical need for patients unable to achieve sustained cholesterol control with existing therapies.The Motley FoolMicron Makes the $1 Trillion Club a Little More CrowdedMicron passed $1 trillion in market value, driven by AI demand for high-bandwidth memory and long-term contracts. Eli Lilly's gene-editing therapy showed a 62% LDL reduction in a Phase 1B trial, and Zscaler reported Q2 revenue of $850.5 million but cut its free cash flow margin guidance.TimeA One-Time Experimental Treatment Might Control Cholesterol for LifeVerve Therapeutics, a company owned by Eli Lilly Co., published Phase 1 clinical trial results in the New England Journal of Medicine for VERVE-102, a one-time gene therapy targeting the PCSK9 gene to lower LDL cholesterol. Among 35 study participants followed for about 18 months, the therapy reduced LDL cholesterol by 9% to 62% depending on dose, with side effects limited to temporarily elevated liver enzyme levels. If proven safe and effective in larger trials, the therapy could offer lifelong cholesterol control with a single infusion, potentially replacing daily statin pills or recurring injections.BioPharma DiveEarly data for heart drug affirm Lilly’s billion-dollar bet on VerveEli Lilly's experimental base editing medicine VERVE-102 succeeded in an early-stage trial, reducing low-density lipoprotein by up to 62% and sustaining reductions for up to 18 months in patients with genetically elevated cholesterol or early-onset heart disease. The drug, acquired through Lilly's $1 billion buyout of Verve Therapeutics, showed PCSK9 level reductions between 55% and 88% across six dose levels, with no treatment-related adverse events reported among 35 enrollees. Lilly plans to begin a Phase 2 study by the end of 2026, potentially strengthening its position in metabolic diseases.BioSpaceLilly is pharma’s top dog, placing first in innovation and invention: IDEAEli Lilly has become the first pharmaceutical company to rank first in both innovation and invention categories in IDEA Pharma's eight-year history, supported by a 45% year-on-year surge in annual earnings to $65.2 billion in 2025, driven primarily by its incretin franchise including Mounjaro ($23B, up 99% YoY) and Zepbound ($13.5B, up 175% YoY). The company reinvested its financial gains into its development pipeline, securing key approvals including weight-loss pill Foundayo, Omvoh's Crohn's disease expansion, and Inluriyo for breast cancer, while also acquiring Verve Therapeutics and SiteOne Therapeutics to boost its invention rating. Merck retained its second-place innovation ranking, while Sanofi made the most dramatic move, jumping 19 spots to third place.BioSpaceLilly’s Verve gambit pays off as base editor cuts cholesterol in early studyEli Lilly's base editor VERVE-102 demonstrated a 62% reduction in LDL cholesterol in a Phase 1b trial for heterozygous familial hypercholesterolemia, vindicating the company's $1.3 billion acquisition of Verve Therapeutics completed in June 2025. The single-dose gene therapy also achieved 51% to 88% reduction in PCSK9 protein levels, with a Phase 2 study planned before year-end. Financial analysts noted lingering skepticism about the commercial viability of gene therapies for cholesterol, though they acknowledged the potential synergy with Lilly's existing cardio-metabolic portfolio.